🏛️ Verified NIH Record • Updated 2026-05-07

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT06879041)

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

Who can join: Review the eligibility criteria below.

Location: Research Site — Palo Alto, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (16 Sites)

  • Research Site — Palo Alto, California
  • Research Site — San Diego, California
  • Research Site — Miami, Florida
  • Research Site — Tampa, Florida
  • Research Site — Chicago, Illinois
  • Research Site — Metairie, Louisiana
  • Research Site — Boston, Massachusetts
  • Research Site — Rochester, Minnesota
  • Research Site — Omaha, Nebraska
  • Research Site — New York, New York
  • Research Site — Cleveland, Ohio
  • Research Site — Portland, Oregon
  • Research Site — East Melbourne,
  • Research Site — CapeTown,
  • Research Site — Durban,
  • Research Site — Pretoria,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗